Making Motion: Power Integrations Inc., Cloud Peak Energy (NYSE:CLD), Titan Pharmaceuticals (NASDAQ:TTNP), Northwest Biotherapeutics (NASDAQ:NWBO)

Posted by on Jan 15, 2016

Senior Housing Properties Trust (NYSE:SNH) shares advanced 0.60% in last trading session and ended the day at $15.08. SNH Gross Margin is 62.50% and its has a return on assets of 2.40%. Senior Housing Properties Trust (NYSE:SNH) quarterly performance is -5.97%.

Senior Housing Properties Trust (NYSE: SNH) declared a quarterly dividend of $0.39 per share, or $1.56 annualized. The dividend will be payable on February 23, 2016, to stockholders of record on January 22, 2016, with an ex-dividend date of January 20, 2016.

Power Integrations Inc. (NASDAQ:POWI) ended the last trading day at $43.23. Company weekly volatility is calculated as 3.87% and price to cash ratio as 8.14. Power Integrations Inc. (NASDAQ:POWI) showed a weekly performance of -2.55%.

Power Integrations (NASDAQ: POWI) will release its fourth-quarter financial results after market hours on Thursday, February 4, 2016. The company will conduct a conference call that day beginning at 1:30 p.m.

On 14 January, Cloud Peak Energy Inc. (NYSE:CLD) shares remains unchanged and was closed at $1.44. CLD EPS growth in last 5 year was -15.40%. Cloud Peak Energy Inc. (NYSE:CLD) year to date (YTD) performance is -30.77%.

Cloud Peak Energy Inc. (NYSE:CLD), one of the largest U.S. coal producers and the only pure-play Powder River Basin (“PRB”) coal company, plans to announce its fourth quarter and full year 2015 financial results on February 17, 2016, after the markets close.

Titan Pharmaceuticals Inc. (NASDAQ:TTNP) shares moved down -12.02% in last trading session and ended the day at $3.00. TTNP has a return on assets of -53.10%.

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and partner Braeburn Pharmaceuticals announced that the Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted 12 to 5 in favor of approving Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction, in stable patients receiving 8mg or less per day of buprenorphine. The Committee’s vote followed presentation and discussion of data regarding Probuphine’s efficacy, safety, and risk-benefit profile.

Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) caters to the Healthcare space. Its weekly performance is -10.82%. On the last day of trading company shares ended up at $2.06. Northwest Biotherapeutics, Inc. (NASDAQ:NWBO) distance from 50-day simple moving average (SMA50) is 1.30%.

Northwest Biotherapeutics (NWBO) issued the statement addressing the sharp decline in the Company’s stock: Global markets are experiencing serious concerns, many biotech companies’ stocks have fallen dramatically, and NW Bio believes that its stock is being heavily impacted by these serious adverse market conditions. NW Bio is not aware of any fundamental Company-related reason for the substantial decline in the price of the Company’s stock at this time.

Leave a Reply

Your email address will not be published. Required fields are marked *